HRP-Fusion Model Improves HER2-Positive Breast Cancer Response Prediction; HER2-Targeted Therapy Landscape Expands
HRP-Fusion improved pCR prediction in HER2-positive breast cancer at ESMO TAT Asia 2026; experts also reviewed emerging endometrial targets and equitable access to HER2 therapies.